FIGURE SUMMARY
Title

Danggui Shaoyao San ameliorates the lipid metabolism via the PPAR signaling pathway in a Danio rerio (zebrafish) model of hyperlipidemia

Authors
Wang, Y., Pan, Y., Hou, M., Luo, R., He, J., Lin, F., Xia, X., Li, P., He, C., He, P., Cheng, S., Song, Z.
Source
Full text @ Biomed. Pharmacother.
Fig. 1

BPC figure of Danggui Shaoyao San (DSS) in positive ion mode (A) and in negative ion mode (B).

Fig. 2

No significant phenotypic abnormalities were observed in zebrafish following treatment with Danggui Shaoyao San (DSS). a: The status of fertilized eggs after 1 day of intervention with DSS; b: The status of fertilized eggs after 5 days of intervention with DSS; c: The hatching time of fertilized eggs following DSS intervention; d: The hatching rate of fertilized eggs after DSS intervention, N = 10.

Fig. 3

Danggui Shaoyao San reduces lipid deposition in a hyperlipidemic zebrafish model. a: Flowchart illustrating the establishment of the hyperlipidemia model; b: Alterations in zebrafish body weight following high-fat diet feeding. Compared with the control group, * P < 0.05, * * P < 0.01, N = 10; c: Changes in zebrafish body weight before and after the induction of hyperlipidemia. Compared with the model group, * * P < 0.01, N = 10; d: Oil Red O staining results of tail vessels of larval fish. Compared with the model group, * * P < 0.01, N = 8; e: Oil Red O staining results of the liver of adult fish. Compared with the model group, * * P < 0.01, N = 3; A: the control group; B: the model group; C: the 50 μg/ml DSS group; D: the 100 μg/ml DSS group; E: the 200 μg/ml DSS group; F: the atorvastatin group.

Fig. 4

Danggui Shaoyao San can enhance locomotor activity and regulate lipid metabolism in a zebrafish hyperlipidemia model. a: Swimming trajectory of zebrafish. b: Statistical analysis of low-speed swimming time. c: Statistical analysis of high-speed swimming time. d: Statistical analysis of medium-speed swimming time. e: Statistical analysis of the medium-speed swimming distance; TG (f), TC (g), LDL-C (h), HDL-C (i), SOD (j), CAT (k), MDA (l), and GSH-PX (m) contents in the liver tissue of adult zebrafish. A: the control group; B: the model group; C: the 50 μg/ml DSS group; D: the 100 μg/ml DSS group; E: the 200 μg/ml DSS group; F: the atorvastatin group. Compared with the model group, * P < 0.05, * * P < 0.01, N = 6.

Fig. 5

Network pharmacology analysis of Danggui Shaoyao San in the treatment of hyperlipidemia. a: Predictive Venn diagram of potential targets of Danggui Shaoyao San against hyperlipidemia; b: PPI network of hub genes involved in lipid metabolism; c: PPI network of the target genes for treating hyperlipidemia with Danggui Shaoyao San; d: Enrichment pathway maps for GO analysis and KEGG analysis of Danggui Shaoyao San; e: Molecular docking results.

Fig. 6

GEO analysis of clinical datasets for hyperlipidemia. a: Heatmap of DEGs in the GSE3059 dataset; b: Volcano plot depicting the differential gene expression in the GSE3059 dataset; c: Venny map of GSE3059 targets and core targets of hyperlipidemia; d: Upregulation and downregulation status of the intersecting genes; e: Pathway diagram of the PPAR signaling pathway; f: GO analysis and KEGG analysis enrichment pathway map.

Fig. 7

Danggui Shaoyao San regulates the expression of genes associated with the PPAR signaling pathway in the zebrafish hyperlipidemia model. a: The mRNA expression level of HMGCR; b: The mRNA expression level of PPARγ; c: The mRNA expression level of PPARα; d: The mRNA expression level of ABCA1; e: The mRNA expression level of HDL; f: The mRNA expression level of CYP7A1; g: The mRNA expression level of SREBP1; h: The mRNA expression level of SREBP2; A: the control group; B: the model group; C: the 50 μg/ml DSS group; D: the 100 μg/ml DSS group; E: the 200 μg/ml DSS group; F: the atorvastatin group; Compared with the model group, * * P < 0.01, N = 15.

Fig. 8

Danggui Shaoyao San upregulates PPARγ and ABCA1 proteins in the liver of the zebrafish hyperlipidemia model. a: Western blotting for PPARγ and ABCA1; b: Statistics of relative PPARγ and ABCA1 protein expression; c-d: Immunofluorescence (IF) for PPARγ and ABCA1; e-f: Fluorescence intensity of PPARγ and ABCA1. A: the control group; B: the model group; C: the 50 μg/ml DSS group; D: the 100 μg/ml DSS group; E: the 200 μg/ml DSS group; F: the atorvastatin group; Compared with the control group, ##P < 0.01; Compared with the model group, * P < 0.05, * * P < 0.01, N = 3.

Fig. 9

The mechanism by which Danggui Shaoyao San improves hyperlipidemia by regulating the PPAR signaling pathway.

Fig. Abs

Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Biomed. Pharmacother.
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.